Antibiotice Ia (ATB) — Capital Reinvestment Ratio
Antibiotice Ia (ATB) has a Capital Reinvestment Ratio of 2.63x as of June 2026, meaning it reinvests 3% of its operating cash flow (RON18.71 Million) in capital expenditures (RON49.25 Million). See Antibiotice Ia free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Antibiotice Ia Capital Reinvestment Ratio (2022–2025)
This chart tracks Antibiotice Ia's Capital Reinvestment Ratio across 4 annual periods. See financial flexibility index of Antibiotice Ia to measure the company's free cash flow as a share of total liabilities.
Annual Capital Reinvestment Ratio for Antibiotice Ia (2022–2025)
Year-by-year Capital Reinvestment Ratio for Antibiotice Ia from 2022 to 2025. For the full cash flow conversion analysis, see Antibiotice Ia (ATB) cash flow conversion.
| Year | Reinvestment Ratio | Operating CF (RON) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 1.97x | RON72.44 Million | RON142.61 Million | ▲ +61.3% |
| 2024 | 1.22x | RON95.15 Million | RON116.16 Million | ▲ +52.5% |
| 2023 | 0.80x | RON122.46 Million | RON98.04 Million | ▲ +132.2% |
| 2022 | 0.34x | RON115.66 Million | RON39.88 Million | — |